Biotech · Private company
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Track this companyFree. Adds Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials103 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- aleniglipronPhase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- AleniglipronPhase 2 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
- AleniglipronPhase 2 · Obesity, Overweight, or Chronic Weight ManagementClinicalTrials.gov · fetched Nov 12, 2026
- GSBR-1290Phase 2 · Overweight or ObesityClinicalTrials.gov · fetched Nov 12, 2026
- AleniglipronPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- GSBR-1290Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- GSBR-1290 (Capsule/Tablet)Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Aleniglipron Hepatic Impairment StudyPHASE1 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07872033 · fetched Nov 12, 2026
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)PHASE3 · RECRUITING · started Jul 17, 2026ClinicalTrials.gov NCT07654374 · fetched Nov 12, 2026
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)PHASE3 · RECRUITING · started Jul 13, 2026ClinicalTrials.gov NCT07654361 · fetched Nov 12, 2026
- Aleniglipron Phase 2 in Type 2 Diabetes MellitusPHASE2 · COMPLETED · started Dec 1, 2025ClinicalTrials.gov NCT07400588 · fetched Nov 12, 2026
- Aleniglipron Phase 2 Body Composition StudyPHASE2 · COMPLETED · started Aug 15, 2025ClinicalTrials.gov NCT07169942 · fetched Nov 12, 2026
- A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityPHASE2 · COMPLETED · started Dec 20, 2024ClinicalTrials.gov NCT06703021 · fetched Nov 12, 2026
- A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityPHASE2 · COMPLETED · started Oct 28, 2024ClinicalTrials.gov NCT06693843 · fetched Nov 12, 2026
- A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsPHASE1 · UNKNOWN · started Oct 2, 2023ClinicalTrials.gov NCT06139055 · fetched Nov 12, 2026
- A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy ParticipantsPHASE1 · COMPLETED · started Apr 24, 2023ClinicalTrials.gov NCT05893043 · fetched Nov 12, 2026
- Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusPHASE1_PHASE2 · COMPLETED · started Jan 9, 2023ClinicalTrials.gov NCT05762471 · fetched Nov 12, 2026